Generic Product News (November 2018)
MARKETED BY: Mylan N.V.
COMPARE TO: Adcirca
INDICATION: Mylan is launching tadalafil to treat pulmonary arterial hypertension, with the goal of improving the ability to exercise. Tadalafil is FDA approved as the first generically equivalent drug to Adcirca, with 180 days of exclusive marketing.
DOSAGE FORM: Oral tablet
FOR MORE INFORMATION: mylan.com
MARKETED BY: Medicure Inc
COMPARE TO: Nitropress
INDICATION: The FDA has approved sodium nitroprusside (SNP) as therapeutically equivalent to Nitropress as a generic cardiovascular drug. SNP can be used to induce hypotension during surgery to reduce bleeding, lower blood pressure in patients undergoing a hypertensive crisis, and treat acute congestive heart failure.
DOSAGE FORM: Intravenous injection
FOR MORE INFORMATION: medicure.com
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE TABLETS
MARKETED BY: Upsher-Smith
COMPARE TO: Lomotil
INDICATION: Atropine sulfate tablets and diphenoxylate hydrochloride are FDA approved as an AA-rated equivalent to Lomotil to treat diarrhea and irritable bowel syndrome. The tablets contain 2.5 mg of diphenoxylate hydrochloride and 0.025 mg of atropine sulfate. Because they are a schedule V-controlled substance with potential for abuse, caution should be taken when prescribing.
DOSAGE FORM: Tablet
FOR MORE INFORMATION: upsher-smith.com
MARKETED BY: Teva Pharmaceutical Industries Ltd
COMPARE TO: EpiPen, EpiPen Jr
INDICATION: The FDA has approved Teva’s epinephrine auto-injector as the first generic equivalent to EpiPen, an emergency injectable treatment for allergic reactions, including life-threatening anaphylaxis. The auto-injector has been approved for adults and pediatric patients who weigh more than 33 lb. Severe allergic reactions can be triggered by foods, insect bites and stings, latex, medications, and more and affect about 1 in 50 Americans. Carrying epinephrine at all times is crucial for patients with severe allergies or those who have suffered from anaphylaxis before.
DOSAGE FORM: Injection
FOR MORE INFORMATION: tevapharm.com